<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066648</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2105</org_study_id>
    <nct_id>NCT03066648</nct_id>
  </id_info>
  <brief_title>Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS</brief_title>
  <official_title>Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination
      with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine in AML and high risk
      MDS patients, and to identify recommended doses for future studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is comprised of five combination arms:
Evaluation of a fixed dose of the standard of care agent decitabine, in combination with fixed dose PDR001 (Arm 1)
Evaluation of a fixed dose of the standard of care agent decitabine in combination with escalating dose MBG453 (Arm 2)
Evaluation of a fixed dose of the standard of care agent decitabine in combination with fixed dose of PDR001 and escalating dose of MBG453 (Arm 3) *
Evaluation of an escalating dose of MBG453
Evaluation of a fixed dose of PDR001 in combination with an escalating dose of MBG453
The evaluation of decitabine with the combination of PDR001 and MBG453 (Arm 3) will start after Novartis and Investigator's review of the available safety and tolerability data from each of the first two cohorts in Arm 1 and Arm 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MBG453 single agent treatment or MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>2 months</time_frame>
    <description>The incidence of DLTs during the first two cycles of treatment with MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>1 month</time_frame>
    <description>The incidence of DLTs during the first cycle of treatment with MBG453.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of MBG453 single agent treatment or MBG453 in combination with PDR001 or PDR001 and/or MBG453 in combination with decitabine.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of PDR001, MBG453 and decitabine.</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PDR001, MBG453 and decitabine</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PDR001, MBG453 and decitabine</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of PDR001, MBG453 and decitabine</measure>
    <time_frame>24 months</time_frame>
    <description>Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration vs time profile of PDR001, MBG453 and decitabine</measure>
    <time_frame>24 months</time_frame>
    <description>Concentration vs. time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine ORR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine BOR in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine PFS in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine TTP in each arm of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine DOR in each arm of the study</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Leukemia</condition>
  <condition>Leukemia, Myeloid</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Preleukemia</condition>
  <condition>Bone Marrow Diseases</condition>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Decitabine and PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine in combination with PDR001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine and MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine in combination with MBG453</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine in combination with PDR001 and MBG453</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBG453 alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBG453 and PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBG453 in combination with PDR001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.</description>
    <arm_group_label>Decitabine and MBG453</arm_group_label>
    <arm_group_label>Decitabine and PDR001</arm_group_label>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <other_name>5-aza-2'-deoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.</description>
    <arm_group_label>Decitabine and PDR001</arm_group_label>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <arm_group_label>MBG453 and PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBG453</intervention_name>
    <description>MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).</description>
    <arm_group_label>Decitabine and MBG453</arm_group_label>
    <arm_group_label>Decitabine, PDR001 and MBG453</arm_group_label>
    <arm_group_label>MBG453</arm_group_label>
    <arm_group_label>MBG453 and PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Written informed consent must be obtained prior to any screening procedures

          2. Male or female patients ≥ 18 years of age who present with one of the following:

             Arms 1-3:

               -  Refractory/relapsed AML following ≥1 prior therapies and are deemed by the
                  investigator not to be candidates for standard therapy, including re-induction
                  with cytarabine or other established chemotherapy regimens for patients with AML
                  (patients who are suitable for standard re-induction chemotherapy or
                  hematopoietic stem cell transplantation and willing to receive it are excluded)

               -  De novo AML patients who are suitable for treatment with decitabine (patients who
                  are suitable for standard induction chemotherapy or hematopoietic stem cell
                  transplantation and willing to receive it are excluded)

               -  High risk MDS (patients who are suitable for standard re-induction chemotherapy
                  or hematopoietic stem cell transplantation and willing to receive it are
                  excluded)

             Arms 4-5:

               -  Refractory / relapsed AML following ≥1 prior therapies (Arms 4a &amp; 5a)

               -  High risk MDS who have failed hypomethylating agent therapy (Arms 4b &amp; 5b) (Note:
                  hypomethylating agent failure is defined as progressive disease on
                  hypomethylating agent therapy or lack of clinically meaningful response as deemed
                  by investigator after at least 4 cycles of hypomethylating agent therapy.)

          3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          4. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to
             the institutions guidelines and be willing to undergo a bone marrow aspirate
             and/biopsy at screening, during and at the end of therapy on this study. Exceptions
             may be considered after documented discussion with Novartis.

          5. Arms 1-3: Patients must be fit for standard treatment with decitabine as determined by
             the investigator and as per local decitabine package insert.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Burke</last_name>
      <phone>617-726-5131</phone>
      <email>Mburke19@partners.org</email>
    </contact>
    <investigator>
      <last_name>Andrew M. Brunner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lue</last_name>
      <phone>503-418-2294</phone>
      <email>luem@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Uma Borate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Faccolli</last_name>
      <phone>713-792-2279</phone>
      <email>mafacciolli@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN 00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF4 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

